NewEdge Wealth LLC Has $940,000 Stock Holdings in argenex SE $ARGX

NewEdge Wealth LLC grew its position in argenex SE (NASDAQ:ARGX) by 269.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,118 shares of the company’s stock after purchasing an additional 815 shares during the quarter. NewEdge Wealth LLC’s holdings in argenex were worth $940,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of ARGX. Mirae Asset Global Investments Co. Ltd. lifted its position in argenex by 91.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,828 shares of the company’s stock worth $6,511,000 after acquiring an additional 4,217 shares during the last quarter. American Century Companies Inc. boosted its holdings in argenex by 11.6% during the third quarter. American Century Companies Inc. now owns 229,770 shares of the company’s stock valued at $169,474,000 after acquiring an additional 23,864 shares during the period. US Bancorp DE grew its position in shares of argenex by 37.2% in the third quarter. US Bancorp DE now owns 7,073 shares of the company’s stock valued at $5,217,000 after purchasing an additional 1,919 shares during the last quarter. Allianz Asset Management GmbH grew its position in shares of argenex by 21.3% in the third quarter. Allianz Asset Management GmbH now owns 3,671 shares of the company’s stock valued at $2,708,000 after purchasing an additional 645 shares during the last quarter. Finally, Alta Wealth Advisors LLC bought a new position in shares of argenex in the third quarter worth about $623,000. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently weighed in on ARGX shares. Zacks Research raised argenex from a “strong sell” rating to a “hold” rating in a research report on Friday, February 20th. HC Wainwright lifted their price target on argenex from $915.00 to $940.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Deutsche Bank Aktiengesellschaft upgraded argenex from a “hold” rating to a “buy” rating in a report on Tuesday, March 10th. Wells Fargo & Company increased their price objective on argenex from $1,247.00 to $1,260.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Finally, Citizens Jmp raised their price objective on shares of argenex from $925.00 to $944.00 and gave the stock a “market outperform” rating in a research note on Friday, February 27th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, argenex has a consensus rating of “Moderate Buy” and an average target price of $1,017.78.

argenex Stock Up 2.4%

argenex stock opened at $822.13 on Friday. The business has a 50 day moving average price of $759.30 and a two-hundred day moving average price of $816.87. argenex SE has a 12 month low of $510.05 and a 12 month high of $934.62. The stock has a market cap of $51.13 billion, a price-to-earnings ratio of 36.60, a price-to-earnings-growth ratio of 1.28 and a beta of 0.46.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. The company had revenue of $1.31 billion for the quarter. argenex had a return on equity of 33.28% and a net margin of 31.31%. On average, analysts expect that argenex SE will post 25.08 earnings per share for the current fiscal year.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.